Numerai GP LLC Has $466,000 Stock Position in Haemonetics Co. (NYSE:HAE)

Numerai GP LLC lowered its position in Haemonetics Co. (NYSE:HAE) by 60.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,968 shares of the medical instruments supplier’s stock after selling 9,111 shares during the quarter. Numerai GP LLC’s holdings in Haemonetics were worth $466,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of HAE. TD Waterhouse Canada Inc. bought a new stake in shares of Haemonetics during the 4th quarter worth about $25,000. Covestor Ltd lifted its holdings in Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 439 shares during the last quarter. Whittier Trust Co. bought a new stake in Haemonetics during the fourth quarter worth approximately $62,000. Parkside Financial Bank & Trust boosted its position in Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 240 shares during the period. Finally, AlphaQuest LLC grew its holdings in Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $143,000 after purchasing an additional 1,826 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Stock Up 1.0%

Shares of HAE opened at $69.36 on Friday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The company has a 50-day simple moving average of $62.88 and a 200-day simple moving average of $71.24. Haemonetics Co. has a 52 week low of $55.30 and a 52 week high of $96.14. The firm has a market capitalization of $3.48 billion, a P/E ratio of 27.31, a P/E/G ratio of 1.11 and a beta of 0.32.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.02. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. The firm had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. During the same period in the previous year, the company posted $0.90 earnings per share. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. On average, equities research analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on HAE shares. Raymond James restated a “strong-buy” rating and issued a $105.00 price objective (down from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and cut their target price for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. JMP Securities lowered their price target on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research report on Friday, February 7th. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Barrington Research decreased their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $97.89.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.